R.A. Session II's Net Worth
$18.4 Million
Who is R.A. Session II?
R.A. Session II has an estimated net worth of $18.4 Million. This is based on reported shares across multiple companies, which include Taysha Gene Therapies, Inc., AveXis, Inc., and Chardan Healthcare Acquisition 2 Corp..
SEC CIK
R.A. Session II's CIK is 0001701846
Past Insider Trading and Trends
2021 was R.A. Session II's most active year for acquiring shares with 3 total transactions. R.A. Session II's most active month to acquire stocks was the month of February. 2023 was R.A. Session II's most active year for disposing of shares, totalling 7 transactions. R.A. Session II's most active month to dispose stocks was the month of April. 2021 saw R.A. Session II paying a total of $529,102.40 for 242,218 shares, this is the most they've acquired in one year. In 2023 R.A. Session II cashed out on 748,595 shares for a total of $388,733.84, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Taysha Gene Therapies, Inc. (TSHA) Snapshot price: $2.09
President and CEOR.A. Session II owns 8,871,747 units of Common Stock which is worth $18,541,951.23. In the year 2020 R.A. Session II acquired a total of 293,814 shares in Taysha Gene Therapies, Inc. at a cost of $529,102.40, R.A. also disposed a total of 549,095 shares of Taysha Gene Therapies, Inc. equalling to $388,733.84.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -0.96% | -85.87K |
$0.71 | -$60,770.73 | 8.87M |
Jul 12 - Jul 13
| |||
Form 4
| -0.32% | -28.61K |
$0.70 | -$20,119.13 | 8.96M |
Jun 22 - Jun 23
| |||
Form 4
| -4.61% | -434.62K |
$0.71 | -$307,843.98 | 8.99M |
Jun 20 - Jun 21
| |||
Form 4
| +2.74% | 251.3K |
—
|
—
| 9.42M |
Mar 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 23
| |||
Form 4
| +0.46% | 42.52K |
$12.44 | $529,102.40 | 9.19M |
Nov 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
AveXis, Inc. No price found
Sr. VP, Corp StrategyR.A. Session II used to own units in Common Stock but no longer holds any shares there. In the year 2017 R.A. Session II filed a total of 5 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -1.67K |
—
|
—
|
0
|
May 15
| |||
Form 4
|
∞
| 1.67K |
—
|
—
| 1.67K |
Mar 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Chardan Healthcare Acquisition 2 Corp. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||